Multicenter phase II study of adding bi-weekly cetuximab to oral S-1 therapy in advanced colorectal cancer who have failed prior oxaliplatin and irinotecan-based therapies

ABSTRACT: Interventions: adding bi-weekly cetuximab to oral S-1 therapy Primary outcome(s): Progression free survival Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2621958 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR